This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Lithium (stopping treatment)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • abrupt withdrawal of lithium treatment in a patient with bipolar disorder increases the risk of recurrence of a major episode of illness - lithium treatment should be gradually discontinued over at least 4 weeks to reduce the risk (and preferably over a period of up to 3 months, particularly if the patient has a history of manic relapse (even if they have been started on another antimanic agent) (2))
    • during dose reduction and for 3 months after lithium treatment is stopped, monitor the person closely for early signs of mania and depression
  • if a patient is to have a major operation, it is wise to stop lithium treatment for 24 hours before the operation; provided serum electrolytes are normal. Lithium treatment should usually be restarted soon after the operation (1)
  • discontinuation of lithium prophylaxis should be discussed between GP, specialist and patient

Notes:

  • when lithium treatment is stopped or is about to be stopped abruptly, prescribers should consider changing to monotherapy with an atypical antipsychotic or valproate, and then monitor closely for early signs of mania and depression

Reference:

  1. Drug and Therapeutics Bulletin 1999; 37 (3): 22-24.
  2. NICE (April 2018). Bipolar Disorder.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.